The Future of ADC: Where to Go?
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…
Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…
There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…
Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…
Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…
Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…
CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…
Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…
Bioconjugation with engineered unnatural amino acids In addition to the sulfur monoclonal antibody technique, the addition of non-standard amino acids (ncAA) provides another possibility for site-specific conjugation. This technique uses amino acidsRead More…
Site-specific bioconjugation of engineered antibodies Advances in bioorthogonal chemistry and protein engineering have contributed to the production of more uniform ADC. Although there are many attachment methods available for natural McAbs, site-specificRead More…